NCT04280328View on ClinicalTrials.gov

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

September 21, 2021

Study Completion Date

March 1, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Ciforadenant

100 mg orally twice daily for 28-day cycles

DRUG

daratumumab

"16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1"

Trial Locations (1)

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors
All Listed Sponsors
lead

Corvus Pharmaceuticals, Inc.

INDUSTRY

NCT04280328 - Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter